<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01443689</url>
  </required_header>
  <id_info>
    <org_study_id>BKCR-BURN-1.0(2011)</org_study_id>
    <nct_id>NCT01443689</nct_id>
  </id_info>
  <brief_title>Allogenic Stem Cell Therapy in Patients With Acute Burn</brief_title>
  <official_title>A Phase Ι/Π Study of Human Cord Blood Mononuclear Cells and Human Umbilical Cord Mesenchymal Stem Cells Transplantation in Patients With Acute Burn</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shenzhen Beike Bio-Technology Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Second Affiliated Hospital of Kunming Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Shenzhen Beike Bio-Technology Co., Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Burn trauma,especially extensive ones, remains a life-threatening local and general
      inflammatory condition destroying the skin and underlying tissues, and resulting in serious
      sequelae. Remarkable progress has been achieved during last 30 years，stem cell therapy plays
      an important role in this progress. Human umbilical cord mesenchymal stem cells (hUCMSCs) and
      human cord blood mononuclear cells (hCBMNCs) have been shown to have the ability to modulate
      the immune response and enhance angiogenesis, suggesting the novel and promising therapeutic
      strategy for burn. In this study, the safety and efficacy of hUCMSCs and hCBMNCs
      transplantation will be evaluated in patients with acute burn.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To investigate the safety and efficacy of human cord blood mononuclear cells and human
      umbilical cord mesenchymal stem cells transplantation in patients of Acute, Moderate-Severe,
      Full-thickness burn.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>July 2011</start_date>
  <completion_date type="Anticipated">July 2013</completion_date>
  <primary_completion_date type="Anticipated">March 2013</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The ratio of wound contraction and re-epithelialisation</measure>
    <time_frame>6 months after treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Complete healing time for investigated burn area</measure>
    <time_frame>6 months after treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Vancouver Scar Scale</measure>
    <time_frame>6 months after treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of infections and bleedings in burn wounds</measure>
    <time_frame>6 months after treatment]</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Engraftment assessment: Vitality of the graft</measure>
    <time_frame>6 months after treatment]</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>McGill pain Questionnaire</measure>
    <time_frame>6 months after treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Adverse Events and Serious Adverse Events</measure>
    <time_frame>6 months after treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Burns</condition>
  <arm_group>
    <arm_group_label>Group1 :Conventional plus hUCMSCs treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be given conventional therapy plus human cord mesenchymal stem cells transplantation with a 6 months follow-up.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2: Conventional plus hCBMNCs and hUCMSCs therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be given conventional therapy plus combination of hCBMNCs together with hUCMSCs transplantation with a 6 months follow-up.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3:Conventional therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will be given conventional therapy only with a 6 months follow-up.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>human umbilical cord mesenchymal stem cells</intervention_name>
    <description>Participants will be given conventional therapy plus hUCMSCs transplantation.</description>
    <arm_group_label>Group1 :Conventional plus hUCMSCs treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>human cord blood mononuclear cells and human umbilical cord mesenchymal stem cells</intervention_name>
    <description>Participants will be given conventional therapy plus and hCBMNCs and hUCMSCs transplantation.</description>
    <arm_group_label>Group 2: Conventional plus hCBMNCs and hUCMSCs therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Conventional therapy</intervention_name>
    <description>Participants will be given conventional therapy only.</description>
    <arm_group_label>Group 3:Conventional therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Between age 18- 65 years, both gender.

          -  Diagnosed with Acute, Moderate-Severe, full-thickness burn:

        Burn occurring within the 72 hours prior to administration. TBSA 20-55%, third degree
        wounds surface area &lt; 19 % ;

          -  Willing to sign the Informed Consent Form.

        Exclusion Criteria:

          -  All other burns except thermal origin.

          -  Chronically malnourished, poor medical condition or shock

          -  Systemic inflammatory response syndrome (SIRS) or septicopyemia

          -  Moderate-severe inhalation injury airways to lung

          -  HIV+

          -  Autoimmune disease, e.g. lupus erythematosus, multiple sclerosis.

          -  Severe pulmonary and hematological disease, malignancy or hypo-immunity.

          -  Currently undertaking other treatment that may affect the safety/efficacy of stem
             cells.

          -  Pregnancy or lactation

          -  Enrollment in other trials in the last 3 months.

          -  Other criteria the investigator consider improper for inclusion.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jinfeng Fu</last_name>
    <phone>86-871-5351281</phone>
    <email>ynfjf@hotmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>The Second Affiliated Hospital of Kunmming Medical College</name>
      <address>
        <city>Kunming</city>
        <state>Yunnan</state>
        <zip>650033</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jinfeng Fu</last_name>
      <phone>86-871-5351281</phone>
      <email>ynfjf@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Jinfeng Fu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 27, 2011</study_first_submitted>
  <study_first_submitted_qc>September 29, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 30, 2011</study_first_posted>
  <last_update_submitted>November 26, 2012</last_update_submitted>
  <last_update_submitted_qc>November 26, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 28, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Extensive Burn</keyword>
  <keyword>Human Cord Blood Mononuclear Cells</keyword>
  <keyword>Human Umbilical Cord Mesenchymal Stem Cells</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Burns</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

